HelenaAYuMD

Instructor, Medicine, Weill Cornell Med College

Overview of Dr. Yu

Dr. Helena Yu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from University of Michigan Medical School and has been in practice 10 years. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(612) 293-0597

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
University of Michigan Medical SchoolClass of 2007

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2010 - 2025
PA State Medical License 2007 - 2010

Clinical Trials

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer Start of enrollment: 2004 Aug 01
Completed
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2013 Oct 15
Completed
Phase 1
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients Start of enrollment: 2014 Jul 01
Completed
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Start of enrollment: 2017 Mar 01
Completed
Phase 1, Phase 2
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Start of enrollment: 2018 Jun 12
Active, not recruiting
Phase 1
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer Start of enrollment: 2019 Jan 17
Active, not recruiting
Phase 1
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2020 Dec 28
Recruiting
Phase 3
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Start of enrollment: 2020 May 28
Recruiting
Phase 2
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2021 Sep 30
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

37 citations
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
Noura J Choudhury, Antonio Marra, Jane S Y Sui, Jessica Flynn, Soo-Ryum Yang
Journal of Thoracic Oncology. 2023-04-01
66 citations
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
A. Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova
Nature Communications. 2021-06-18
282 citations
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C. Arbour, Emmet Jordan, Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu
Clinical Cancer Research. 2018-01-15

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR Inhibitor
Alexander I Spira, Helena A Yu, Clinical Lung Cancer
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
2019 ASCO Annual Meeting - 6/1/2019
Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018

Press Mentions

Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory CommitteeApril 26th, 2023
Dissolving Knowledge Gaps Regarding EGFR Exon 20 Insertion-Mutant NSCLCJuly 6th, 2022
'Brutal, Relentless' Lung Cancer Kills Dustin Diamond: What Are the Symptoms?February 2nd, 2021
Join now to see all